ClearNote Health has announced that its Avantect test could detect pancreatic cancer in high-risk patients, such as those diagnosed with Type 2 diabetes recently, in a study.
The company revealed the data from the study ‘Epigenomic Blood-based Early Detection of Pancreatic Cancer Employing Cell-free DNA.’
Go deeper with GlobalData
The Avantect Pancreatic Cancer Test primarily assesses alterations in 5-hydroxymethylcytosine (5hmC) signals in cell-free DNA obtained from plasma.
According to the company, the study is designed to describe the DNA-based blood test’s development and validation.
The case-control validation study, which involved 2,150 patient samples, indicated high specificity of 96.9% and early-stage (Stage I/II) sensitivity of 68.3%.
ClearNote Health chief scientific officer Samuel Levy said: “Our unique approach to early detection combines epigenomics with genomic alterations and fragmentomics as input to sophisticated machine learning algorithms.
“This enables us to offer clinicians an early detection test that can be used to guide patient management recommendations and identify pancreatic cancers at early, treatable stages when longer-term patient survival is still possible.”
The test is supported by the company’s automated, 5hmC-based epigenomic platform, which measures active biological events that take place in tumours during the early stages of cancer formation.
This platform enhances DNA fragments through 5hmC labelling to target a subset of dynamically demethylated bases.
Furthermore, the new data confirm that the company’s epigenomic platform is useful for detecting cancer in individuals who are at a higher risk of developing pancreatic cancer. It enables timely detection and intervention of the disease.
